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Abstract Parkinson’s disease (PD) is the second most
common neurodegenerative disorder, leading to a variety
of motor and non-motor symptoms. Interestingly, non-
motor symptoms often appear a decade or more before the
first signs of motor symptoms. Some of these non-motor
symptoms are remarkably similar to those observed in
cases of impaired neurogenesis and several PD-related
genes have been shown to play a role in embryonic or adult
neurogenesis. Indeed, animal models deficient in Nurr1,
Pitx3, SNCA and PINK1 display deregulated embryonic
neurogenesis and LRRK2 and VPS35 have been implicated
in neuronal development-related processes such as Wnt/b-
catenin signaling and neurite outgrowth. Moreover, adult
neurogenesis is affected in both PD patients and PD animal
models and is regulated by dopamine and dopaminergic
(DA) receptors, by chronic neuroinflammation, such as that
observed in PD, and by differential expression of wild-type
or mutant forms of PD-related genes. Indeed, an increasing
number of in vivo studies demonstrate a role for SNCA and
LRRK2 in adult neurogenesis and in the generation and
maintenance of DA neurons. Finally, the roles of PD-
related genes, SNCA, LRRK2, VPS35, Parkin, PINK1 and
DJ-1 have been studied in NSCs, progenitor cells and
induced pluripotent stem cells, demonstrating a role for
some of these genes in stem/progenitor cell proliferation
and maintenance. Together, these studies strongly suggest
a link between deregulated neurogenesis and the onset and
progression of PD and present strong evidence that, in
addition to a neurodegenerative disorder, PD can also be
regarded as a developmental disorder.
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KD Knockdown
KO Knockout
LRRK2 Leucine-rich repeat kinase 2
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NSC Neural stem cell
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PCNA Proliferating cell nuclear antigen
PD Parkinson’s disease
PINK1 PTEN-induced putative kinase 1
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SNpc Substantia nigra pars compacta
SNCA a-Synuclein
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SVZ Subventricular zone
TH Tyrosine hydroxylase
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Introduction
Parkinson’s disease (PD), first described in 1817 by James
Parkinson [1], is the second most common neurodegener-
ative disease after Alzheimer’s disease and the first most
common motor neurodegenerative disease, affecting
approximately 2 % of the population aged 60 years and
older [2, 3]. The disease is characterized by its locomotor
phenotypes, which include resting tremors, difficulty ini-
tiating movement, postural instability, bradykinesia
and rigidity as well as the formation of intracytoplasmic
inclusions or protein aggregates called Lewy bodies, con-
taining insoluble a-synuclein (SNCA) protein. Several
non-motor symptoms of PD have also been described,
including anhedonia [4–8], depression [9], anxiety [10],
olfactory deficits [11–13], sleep disturbances [14, 15] and
cognitive dysfunction [16–18]. These non-motor symptoms
often precede the prototypical motor symptoms of PD by
years or even decades [19, 20]. The PD-associated motor
symptoms primarily result from the degeneration of DA
neurons in the substantia nigra pars compacta (SNpc),
although degeneration has also been observed in the stri-
atum, hippocampus, and neocortex [21]. Interestingly,
changes in DA innervation and DA concentration in the
striatum can occur 20–30 years prior to the onset of any
motor symptoms [22, 23].
Over 90 % of all PD cases appear to occur sporadically
and most of them are idiopathic cases. Most plausibly,
these cases arise from multiple factors acting simulta-
neously, including genetic susceptibility, environmental
factors and, most importantly, age. Familial variants of
PD result from genetic mutations leading to either auto-
somal dominant forms of PD, such as those caused by
mutations in the SNCA, LRRK2, VPS35 or GBA gene, or
autosomal recessive forms of PD, such as those caused by
mutations in the PINK1, Parkin or DJ-1 gene. Several
other genes have been described to confer an increased
susceptibility to PD, including EIF4G1, ATP13A2,
PLA2G6, FBXO7, DNAJC6, DNAJC13, SYNJ1, MAPT,
Pitx3, Nurr1 and UCHL1. Although familial variants of
PD account for up to only 10 % of all cases [24, 25], an
induced pluripotent stem cells (iPSC)-based study has
recently suggested that even in idiopathic cases of PD, the
increased susceptibility of DA neurons is probably enco-
ded in the genome [26]. Moreover, sporadic and genetic
forms of PD have comparable motor phenotypes, imply-
ing that they share common neurodegenerative
mechanisms [27].
No matter what the etiology, in PD, more than 50 % of
SN neurons degenerate before the onset of motor symp-
toms and many of the non-motor symptoms of PD precede
the occurrence of motor symptoms by years or even dec-
ades [19, 28–30]. Some of the prominent non-motor
symptoms described during the premotor phase of PD such
as hyposmia, depression and anxiety are also phenotypes
observed in models of deregulated neurogenesis [31–34]
and medications and treatments for depression and anxiety
have been shown to increase adult neurogenesis (reviewed
in [35]). Although a causative role for neurogenesis in
depression and anxiety has yet to be demonstrated, it is
likely that hyposmia is caused, at least in part, by dereg-
ulated neural stem cell (NSC) activity already occurring
during development and/or in adult NSCs.
NSCs are self-renewing, multipotent progenitors that
give rise to multiple types of neurons and glial cells during
embryonic brain development as well as during adult
neurogenesis (more detailed information in [36–51]). NSCs
represent a potential endogenous source for neuronal
replacement therapy in neurodegenerative disorders such
as PD. Moreover, studies focusing on adult NSCs and
neurogenesis in PD models offer the potential for earlier
diagnosis, stratification and possibly therapeutic treatments
for this debilitating disease.
Evidence for a developmental component of PD:
deregulated embryonic neurogenesis
A number of PD-associated genes have been implicated in
DA neuronal development during embryogenesis. Here, we
discuss studies using mice deficient for Nurr1, Pitx3, and
SNCA that have demonstrated deregulated embryonic
neurogenesis of DA neurons in the midbrain as well as
studies describing the role of PINK1, LRRK2 and VPS35 in
neuronal development and the altered expression of the
developmentally related brain-derived neurotrophic factor
in PD.
The orphan nuclear receptor, Nurr1, is expressed prin-
cipally in the limbic and ventral midbrain and plays an
important role in the development and maintenance of DA
neurons [52–55]. As previously mentioned, mutations in
the Nurr1 transcription factor have been associated with a
susceptibility to PD [56–60]. Moreover, Nurr1 gene and
Nurr1 protein expression is reduced in DA neurons of the
SN in PD patients [57, 61].
Given its role in the induction of differentiation of
progenitor cells to tyrosine hydroxylase (TH)-positive DA
neurons, it is likely that Nurr1 mutations contribute to PD
pathology early in development, during the formation of
the ventral midbrain DA neuron pool. Indeed, reduced
Nurr1 expression in heterozygous mutant mice leads to
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decreased DA transporter expression [62], decreased TH-
positive neurons in SNpc and less DA concentration in the
dorsal striatum [63]. Moreover, these mice display mor-
phological, biochemical and behavioral phenotypes similar
to those observed in PD, reflecting the reduced number of
DA neurons in the SNpc [62, 64, 65]. Nurr1 also inhibits
expression of pro-inflammatory molecules involved in the
neurotoxic response in microglia and astrocytes [66] and
acts to transcriptionally downregulate SNCA [67].
Reduced expression of Nurr1 would also therefore lead to
an increased inflammatory response, an unregulated
increase in SNCA expression and possibly DA neuron cell
death, further reducing the number of DA neurons in the
developing brain, all factors that increase the risk to
develop PD.
Another PD-susceptibility gene involved in neuronal
development is the Pitx3 gene. The Pitx3 protein is a
transcription factor necessary for terminal differentiation of
TH-expressing neurons in the SN through the potentiation
of Nurr1 transcription [68]. In mice lacking Pitx3, SN
neuronal precursor numbers are dramatically decreased and
these cells fail to produce TH, demonstrating that the Pitx3
protein is important for SNpc development and mainte-
nance [69]. Moreover, overexpression of Pitx3 in ventral
mesencephalon-derived NPCs improves motor function in
a 6-OHDA PD model [70]. As previously mentioned, Pitx3
is necessary for Nurr1-mediated transcription, an important
mechanism in DA neuron development and maintenance.
As such, Pitx3 mutations may increase susceptibility to PD
by a downstream effect on Nurr1 activity and the sub-
sequent reduction in the numbers of DA neurons formed in
the SN during brain development,
Endogenous a-synuclein has also been implicated in DA
neuronal development [71]. In this study, Garcia-Reitboeck
and colleagues describe a reduction in the number of DA
neurons in the SN of mice with a spontaneous deletion of
the SNCA gene, as well as in SNCA knockout (KO) mice,
visible as early as E13.5. Their results demonstrate that a-
synuclein is necessary for the embryonic development of at
least a subpopulation of DA neurons and suggest that PD-
related SNCA mutations may also lead to a reduction in the
number of DA neurons in the developing brain, long before
DA neuronal degeneration even starts. Interestingly, in this
scenario, reduced levels of a-synuclein contribute to an
increased PD risk, although more commonly, it is elevated
a-synuclein levels that are associated to PD. This would
suggest that only a balanced, optimal dosage of a-synuclein
is beneficial for DA neuron formation and maintenance,
while too high as well as too low levels are detrimental.
Additionally, the function of a-synuclein as well as the
dosage effects of this protein might be different during
embryonic development or adulthood (see further discus-
sion of SNCA below).
In the developing mouse brain, PINK1 protein expres-
sion is evident at E15 and increases significantly just before
birth at E19 [72], coinciding with a period of increased
neurogenesis in the brain [73]. PINK1 has recently been
shown to interact with and phosphorylate the embryonic
ectoderm development polycomb histone-methylation
modulator, redistributing it to the mitochondria, resulting
in a favorable change in transcription regulation for neu-
ronal differentiation [74]. PINK1 downregulation in
zebrafish results in delayed brain development, enlarged
ventricles and a moderate decrease in TH-positive neurons
in the diencephalon, likely due to an increase in apoptosis
as evidenced by an increase in active Caspase 3 in these
embryos [75].
LRRK2 expression in the developing mouse brain is
particularly strong in the ventricular zone and SVZ of the
telencephalon during the period of neurogenesis (E11.5 to
E17.5) [76]. Furthermore, LRRK2 is expressed in NSCs
isolated from both the DG and SVZ of E18.5 mice. The
LRRK2 protein may interact with the regulator of neurite
outgrowth during embryonic neurogenesis, CRMP2 [77]
and numerous studies have demonstrated that mutant
LRRK2 overexpression decreases neurite length/out-
growth, while LRRK2 deficits result in an increase of
neurite length and arborization [78–94]. Moreover, LRRK2
has been shown to bind Wnt signaling components (the
DVL proteins) and play a role in the canonical Wnt/b-
catenin signaling pathway, an important pathway for neu-
rogenesis and in particular the development of DA neurons
[83, 95, 96].
Neuronal developmental defects are also visible in the
absence of the PD-related gene, VPS35, discussed in more
detail in the ‘‘Function of PD Genes in neural stem cells’’
section below. Briefly, VPS35 knockdown (KD) in mouse
embryonic hippocampal neurons results in shortened apical
dendrites, reduced dendritic spines and swollen commis-
sural axons [97].
Lastly, brain-derived neurotrophic factor, known to
regulate the differentiation and survival of midbrain DA
neurons [98], displays reduced mRNA expression in the
SNpc of PD models [99, 100].
Evidence for deregulated adult neural stem
cell activity in PD
Neurogenesis in the PD brain
Adult neurogenesis has been described in the human brain
in both the SVZ and the SGZ [46, 47, 101]. Unfortunately,
few studies have been done to examine neurogenesis in the
post-mortem PD brain and those that have been conducted
present conflicting findings.
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A first group of studies has demonstrated that post-
mortem PD brains display deregulated adult neurogenesis.
In these studies, cell proliferation appears to be decreased
in the SGZ and SVZ of PD patients. The number of pro-
liferating cell nuclear antigen (PCNA)-positive adult NSCs
in the SVZ and Nestin-positive precursor cells in the OB
are decreased in the PD-affected post-mortem brain [102]
and a decrease in NSCs correlates with the progression of
PD, while L-Dopa treatment appears to increase NSC
numbers [103]. Moreover, EGF and EGFR levels are also
decreased in the PD striatum and the prefrontal cortex of
PD patients [104] and EGFR-positive neural stem/pro-
genitor cell numbers are decreased in the SVZ of PD
patients [105].
Other groups, however, have demonstrated no change in
NSC proliferation in the PD-affected brain, such is the case
in one study that examined NSC proliferation in the SVZ of
PD patients and control brains [106]. NSCs have been
identified in the SVZ of the aged human brain [107, 108]
and in the SVZ of PD patients [106]. NPCs have been
isolated from post-mortem human cortex and SN of PD
patients [109, 110] and neurospheres have been obtained
from the SVZ of a PD brain, indicating the presence of
adult NSCs [106]. However, idiopathic human PD multi-
potent NPCs isolated from the SN appear to lack key
factors required for neuronal differentiation as they must be
co-cultured with embryonic stem cell-derived neural pre-
cursors to obtain neurons [110].
Neurogenesis defects in PD animal models
Mainly, two animal models for PD have been used to study
neurogenesis: acute lesions formed by either 6-hydroxy-
dopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) administration. Both experi-
mental models replicate the DA neuron degeneration
observed in PD and result in motor phenotypes. Although
neurogenesis in both the SVZ and the SGZ has been shown
to decline with age in rodents [111–113], whether this
phenomenon is exacerbated, inversed or unchanged in PD
animal models is still up for debate.
In one study, MPTP administration in the mouse brain
decreased the number of proliferating cells in the SVZ and
the corresponding DA neuron denervation decreased the
number of PCNA-positive progenitor cells in the SGZ
[102]. In later studies, MPTP administration was shown to
induce apoptosis of migrating neuroblasts (NBs) from the
SVZ [114, 115]. Conversely, MPTP treatment has also
been shown to increase proliferation in the SVZ and the
SGZ [116] and to increase neurogenesis in the SN and OB
[116–119] of mice. Yet in another study, no change in
proliferation or neurogenesis was observed. While MPTP
treatment in mice induced DA denervation of the striatum,
no change in proliferation of the SVZ progenitors was
observed [106].
In macaque monkeys, MPTP treatment has been shown
to deplete DA innervation in the SVZ and reduce the
number of proliferating cells in this area [120]. In another
study focusing on another brain region, MPTP treatment in
the macaque revealed no increase in DA neurogenesis in
the striatum [121].
In a number of studies, 6-OHDA treatment leads to
decreased proliferation of neuronal precursors in the SVZ,
visualized by a decrease in the number of PCNA-
expressing cells in the SVZ of treated rats [102, 122] or a
decrease in the number of BrdU-labeled cells in the SVZ
of treated mice [123]. In the OB, 6-OHDA treatment
results in decreased BrdU labeling in the granule cell
layer (the site of integration for neural progenitors origi-
nating in the SVZ) but increased BrdU labeling in the
glomerular cell layer with a concomitant increase in DA
neurons in the OB, suggesting that DA differentiation is
increased [122–124]. On the other hand, 6-OHDA treat-
ments in rats have also increased proliferation in the SVZ
[125–127]. It is noteworthy that, although proliferation
appeared to be increased, these cells could only differ-
entiate into astroglial cells and not neurons and thus
neurogenesis would appear to be deregulated in these
models as well [125]. Finally, examination of Dcx-posi-
tive NPCs in the SN of mice revealed no change after
6-OHDA injections [128].
Regulation of NSC activity by PD-associated
neuroinflammation
Chronic neuroinflammation has been observed in both PD
patients’ brains and in animal models of PD [129–132], but
how this inflammation affects neurogenesis is only just
being elucidated.
Inflammation-related proteins and molecules such as
TNF-a, inflammatory cytokines and nitric oxide negatively
regulate neurogenesis [133–136], while neurogenesis is
increased in the hippocampus and SVZ by anti-inflamma-
tory drug treatment in the focal traumatic brain injury and
Japanese encephalitis models for acute neuroinflammation
[137–139].
In the 6-OHDA PD model, treatment with anti-inflam-
matory drugs (minocycline or specific COX2 inhibitors)
activates NSC proliferation in the SVZ and oligodendro-
genesis and/or astrogliosis in the affected striatum and in
the SN and even induces a functional regeneration as
shown by rotational behavior experiments [128, 133].
Finally, the inflammatory response and microglia acti-
vation in a MPTP model of PD are partially mediated by
the chemokine receptor CX3CR1 [140], a known regulator
of adult neurogenesis [141].
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Regulation of neurogenesis by dopamine
Dopamine appears to also play a role in the control of
neurogenesis. Indeed, dopamine receptors have been
observed on both neurospheres derived from rodent SVZ
precursors [102, 142, 143] and in vivo on progenitor cells
of the SVZ in mice and rats [102, 144, 145]. Moreover, DA
fibers have been described in close proximity to EGFR-
positive cells (progenitor cells) in the post-mortem human
brain [102]. These DA fibers likely originate from SN cells,
as has been described for non-human primates [120].
An experimentally reduced dopamine level in mice
decreases precursor cell proliferation in both the sube-
pendymal zone and in the SGZ; this effect can be reversed
by a selective D2-like receptor agonist (one of two sub-
families of DA receptors, including the D1, D2 and D3 DA
receptors) [102]. Correspondingly, experimentally induced
dopamine loss decreases SVZ proliferation and EGFR-
positive adult NSCs via D2-like receptors [102, 105, 122,
123, 146]. It appears that dopamine can also exert its
effects on neurogenesis, at least in part, via the D3 receptor.
Activation of the D3 receptor in rats increases proliferation
in the SVZ, RMS and possibly in the SN [147] and also
stimulates OB neurogenesis [145]. In vitro studies have
demonstrated that dopamine can also stimulate cell pro-
liferation in neurospheres through the D3 receptor and may
also stimulate neurogenesis [142].
Function of PD genes in neural stem cells
Studies of PD-related genes, in particular in NSCs, pro-
genitor cells and iPSCs have suggested that these genes
may be important in the regulation of stem/progenitor cell
proliferation, maintenance and differentiation. Below, we
outline the state of the art of this topic for the most com-
mon PD-related genes (reviewed in Table 1).
SNCA (PARK1/PARK4)
The SNCA gene (4q21), located at the PARK1/4 locus,
encodes the protein a-synuclein. Several PD-related SNCA
mutations have been identified. The A53T [148], A30P
[149] and E46K [150] mutations as well as gene duplica-
tions [151] and triplications [152] are the SNCA genetic
variations responsible for the onset of an autosomal dom-
inant form of PD, while other PD-associated mutations
such as the A18T, A29S, H50Q and G51D mutations may
also contribute to PD progression [153–155].
a-Synuclein is a highly conserved protein that is abun-
dantly expressed in the adult brain, but its precise function
is still unknown [156, 157]. Certain studies have, however,
described an involvement of a-synuclein in normal brain
function [158], synaptic plasticity [159, 160] and the reg-
ulation of the presynaptic vesicular pool [161, 162],
including DA release [163]. a-Synuclein has also been
described as a chaperone and described to contribute to
SNARE complex formation [164]. a-Synuclein is a
natively unfolded monomer but it is able to switch from a
helical to a b-sheet structure, aggregate and form fibrils
[156, 157]. In PD brains, a-synuclein is the predominant
protein found in Lewy Body inclusions [165, 166] and the
misfolding and aggregation of this protein into neurotoxic
species is considered central in PD pathogenesis [167].
An increasing number of studies reveal that a-synuclein
plays an important role in neurogenesis. When the SNCA
gene is differentially expressed or bears mutations or the a-
synuclein protein forms aggregates, the neuronal stem cell
pool is negatively regulated and the survival of newly
generated neurons is decreased. The aforementioned sug-
gests that there is a link between neurogenesis, SNCA and
neurodegenerative diseases. If decoded, the details of this
relationship could provide a valuable tool for designing
potential therapies for patients with neurodegenerative
diseases such as PD.
Overexpression of wild-type SNCA
Adult mice overexpressing human wild-type SNCA under
the PDGF promoter were used to investigate adult NSC
proliferation, migration and differentiation [168]. Although
no difference in the number of PCNA-positive proliferating
SVZ or DG cells could be observed between the transgenic
and the control mice, a significant reduction of newly
generated (BrdU positive) neurons was apparent in the OB
and the DG. In particular, DA neurogenesis in the OB was
severely impaired as was evident by the fact that the
number of TH/BrdU double-positive cells was reduced
more than half in the mice overexpressing SNCA. This
effect observed in the OB was accompanied by increased
cell death in the granule layer of the DG and in the OB
[168].
In vitro, SNCA overexpression reduces the number of
secondary neurospheres formed and affects NSC mor-
phology and cell cycle progression, leading to their
accelerated differentiation [169]. However, when the
authors used the same virus to overexpress SNCA in vivo,
no effect was seen on the proliferation of SVZ NSCs, an
observation that agrees with previous study mentioned.
Instead, they observed a delay in the migration of NSCs
through the SVZ/RMS/OB system, evident by an increased
number of NSCs that remained in the neurogenic niche
[169].
A subsequent study using mice overexpressing human
SNCA under the tet-off system investigated if impaired OB
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Table 1 Effect of PD-related genes in NSCs and on neurogenesis
Gene Phenotype Observed effect References
SNCA Overexpression Adult [168]
– proliferation in SVZ and DG
; neurogenesis in OB and DG
: cell death in OB and DG
Embryonic [169]
; formation of secondary spheres
; cell cycle entry of NSCs
: differentiation of NSCs
Adult
– proliferation in SVZ, RMS and OB
– cell death in SVZ, RMS and OB
– differentiation of NSCs into DA neurons in OB
; NSC migration through the RMS
Adult [71]
: DA neurons in SN
Adult [184]
; dendritic length of neurons in DG
: spine density of neurons in DG
; mushroom spines of neurons in DG
Adult [172, 173]
; neurogenesis in DG
: cell death in DG
In vitro
; neurogenesis
: cell death
; neuronal differentiation
Knockout Adult [184]
: neurogenesis in DG
– BrdU? newly generated cells in DG
– proliferation in DG
– cell death in DG
Mutant A30P ; neurogenesis in OB [175]
– proliferation in SVZ
A53T Adult [174]
; neurogenesis in OB
: cell death in OB
Aged mice
; proliferation in SVZ
: cell death in SVZ
; neurogenesis in OB
: cell death in OB
Adult [172]
; neurogenesis in DG
: cell death in DG
In vitro
; neurogenesis
: cell death
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Table 1 continued
Gene Phenotype Observed effect References
LRRK2 Knockout/knockdown Adult [94]
– proliferation in DG
– BrdU? newly generated cells in DG
: early differentiating neurons (DCX? cells) in DG due to delayed maturation
: dendritic arborization and dendritic length
In vitro [197]
– NSC proliferation
: neuronal differentiation
; ROS and cell death of differentiating neurons
In vitro [198]
: (accelerated) neuronal differentiation
Adult
: early differentiating neurons (DCX? cells) in DG
In vitro [199]
; DA neuronal differentiation
: cell death
Mutant G2019S Adult [86]
; proliferation in DG, SVZ and RMS
; survival of newly born neurons in OB and DG
; dendritic arborization and spines
In vitro [200]
; neural differentiation
; proliferation (clonal expansion)
: susceptibility to proteasomal stress
R1441G In vitro [197]
– NSC proliferation
; neuronal differentiation
: ROS and cell death of differentiating neurons
VPS35 Knockout/knockdown Adult [97]
; dendritic arborization and spines
In vitro [197, 218] [199]
; neurite length
PINK1 Knockout/knockdown In vitro [250]
– DA neuronal differentiation
Adult drosophila [254]
; proliferation
In vitro (human NSCs)
; proliferation
Mutant Q456X In vitro [251, 253]
– DA neuronal differentiation
Parkin Knockout/knockdown In vitro [276–278]
– DA neuronal differentiation
DJ-1 Knockout/knockdown In vitro (ESCs) [300]
: sensitivity to proteasomal stress and ROS
– no effect is observed, : increased, ; decreased
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neurogenesis caused by SNCA overexpression could be
rescued when the transgene is silenced [170]. As in the case
of Winner et al., the authors demonstrated a decrease in
NSC proliferation in the SVZ and in the generation of new
neurons in the OB. When SNCA overexpression was
ceased, the amount of new cells in the granule cell layer
was increased but these cells did not manage to become
neurons. On the other hand, glomerular layer neurogenesis
was partially restored. It is worth mentioning that the
amount of newly TH-positive cells was also reduced when
the transgene was active and upon its silencing, the number
of TH-positive cells was increased up to 89 % in the glo-
merular layer of the bulb [170].
A broader investigation concerning a-synuclein was
performed in silico; mice overexpressing human wild-type
SNCA were used to perform a transcriptome analysis of the
striatal brain region [171]. The expression of many genes
implicated in apoptosis, cell cycle progression, neurogen-
esis and synaptic function were impaired, demonstrating
that indeed a-synuclein is involved in many different cell
processes that, when deregulated due to differential SNCA
expression, may influence neurogenesis. Indeed, rat hip-
pocampal NPCs and mouse ESCs overexpressing SNCA
display impaired neuronal differentiation and survival, an
effect that is mediated by increased p53-mediated repres-
sion of Notch-1 signaling [172, 173].
Overexpression of mutated SNCA
OB neurogenesis during aging was investigated in mice
that overexpress either human wild-type (WT) or A53T
mutated SNCA [174]. Among these animals, only the aged
mice bearing the SNCA mutation showed a significant
decrease in proliferation of the SVZ NSCs. In addition,
both transgenic mice revealed a reduction in the total
number of newly generated neurons accompanied by an
increase in apoptosis of neuronal progenitor cells in the
OB. Newly generated TH-positive cells were decreased in
both groups but the effect was more profound in the mice
overexpressing the mutant form of SNCA [174]. This study
demonstrates a correlation between aging and neurogenesis
in the context of WT and mutant SNCA overexpression,
showing that the A53T mutation produces more deleterious
effects with respect to proliferation of NSCs and the sur-
vival of both stem cells and newly generated neurons.
Transgenic mice overexpressing the A30P mutant form
of SNCA display no difference in proliferation in the SVZ,
compared to control mice [175]. However, in the OB, the
amount of newly generated DA neurons is decreased in the
mutant mice. More recently, the same group investigated
the effect of the mutation on hippocampus plasticity and
found that the survival of new hippocampal neurons is
dramatically decreased in these mice [176]. The cause of
this decrease in newly formed neurons has not been
investigated in this model. As such, it would be interesting
to investigate if the decrease in neurons in this model is
also due to decreased survival (increased apoptosis), as was
the case for the A53T SNCA overexpression mouse model.
In addition, the SNCA mutant mice present behavioral
changes such as an increase in anxiety. Olfactory deficits
and behavioral changes such as increased anxiety are also
examples of non-motor symptoms of PD patients, sug-
gesting a role for SNCA variations in non-motor deficits of
PD.
Finally, mice expressing a truncated form of human
SNCA (1–120 SNCA) under the control of the TH promoter
in an endogenous null background developed inclusions in
the SN, motor abnormalities, redistribution of SNARE
proteins and impaired exocytosis [177, 178]. Recently,
these mice were used to generate a new transgenic line by
crossing them with WT mice. Compared to WT or to the
1–120 SNCA transgenic line, a significant increase in the
number of SN DA neurons was observed [71]. The group,
however, did not investigate the correlation between the
increase of TH-positive neurons with increased neurogen-
esis nor did they investigate the proliferation,
differentiation or survival potential of these cells, which
would be an interesting point for future research. If these
questions are answered, they might unveil an interesting
mechanism or point to a certain direction concerning the
specific function of a-synuclein in neurogenesis of the SN.
The sum of these studies demonstrates the deleterious
effects of SNCA overexpression in the mouse brain.
In vitro, WT SNCA overexpression leads to a decrease in
proliferation. Overexpression of WT SNCA in vivo
decreases the number of newly generated TH? neurons via
increased apoptosis of newly generated neurons and a
decrease in cell migration through the RMS. Moreover, the
decrease in the number of newly generated TH? neurons is
even more pronounced and is accompanied by a clear
decrease in SVZ NSC proliferation when a mutated form of
SNCA is expressed. Neurogenesis is a vital ongoing process
in the adult brain and its disruption, via the deregulated
expression or function (incurred by genetic mutations) of
SNCA, could contribute to the non-motor deficits observed
in patients with PD.
Interestingly, olfactory deficits have been described in
mice overexpressing WT SNCA and olfaction impairment
is an early non-motor symptom of PD. In one study, mice
overexpressing SNCA under the Thy1 promoter displayed
impairments in a number of olfactory functions [179]. In
another study, mice overexpressing the human WT SNCA
gene via the mouse SNCA promoter displayed olfactory
deficits such as odor detection impairment, olfactory
memory deficit and impaired odor discrimination [180,
181]. OB neurogenesis was also examined in the latter
780 J. N. Le Grand et al.
123
experiment but no difference in the number of newly
generated neurons in the OB, based on BrdU labeling
assays, was detected. Instead, it is likely that the olfaction
deficits observed in SNCA transgenic mice are due, at least
in part, to impaired growth and branching of dendrites and
the subsequent failed stable integration into the OB of
newly born DA neurons during adult neurogenesis, leading
to a decrease in cell survival, as has been described for an
A30P SNCA overexpressing mouse [182, 183].
Reduced expression of SNCA
Neurogenesis in the adult mammalian brain has also been
investigated in the a/b–SNCA double knockout (DKO)
mouse in the second neurogenic niche of the brain, the DG.
These mice display increased neurogenesis in the DG but
lack any apoptosis phenotype. When human SNCA is
introduced (either as a transgene or a retrovirus), a sub-
stantial impairment in hippocampal neurogenesis and in
dendrite development and morphology is observed [184].
In this study, the group investigated if there was an
increase in the newly generated neurons by injecting the
mice with BrdU. In addition, they used Caspase 3 staining
to examine if the increase that they saw in the new neurons
was balanced by increased apoptosis but they did not find
any difference of cell death between the DKO mice and the
wild type. These observations indicate that the results
obtained indeed represent an increase in neurogenesis. It
would be interesting to investigate the second adult neu-
rogenic niche of this mouse to examine the effect of SNCA
ablation on proliferation of the SVZ stem cells, their
migration and the number of newly generated neurons in
the OB.
Finally, in another study, surprisingly, the number of TH
positive neurons is profoundly reduced in the SN of
developing homozygous and heterozygous SNCA knockout
embryos compared to WT embryos, suggesting that
endogenous SNCA plays an important role in the embry-
onic development of DA neurons [71].
Altogether, the majority of the above-described experi-
ments suggest that overexpression of SNCA (either WT or
mutant forms) decreases the number of newly generated
neurons in the DG, OB and SN of the adult brain, including
DA neurons in the latter two brain regions. This decrease in
DA neurogenesis has been attributed to a multitude of
factors, depending on the study, including decreased NSC
proliferation in the SVZ, decreased survival of newly
generated neurons (increased apoptosis) in the DG and in
the OB as well as decreased cell migration through the
RMS. Moreover, the a/b–SNCA double KO mouse displays
increased neurogenesis in the adult DG. By contrast, one
study describes a decrease in the number of newly gener-
ated DA neurons in the embryonic DG in the SNCA KO
mouse. These seemingly contradictory results hint at a
differential effect of SNCA expression on neurogenesis,
depending on the age of the animal (during embryonic
development vs. in the adult neurogenic niches) or on the
region of the brain being studied (SN vs. OB vs. DG).
Moreover, it appears that SNCA expression levels need to
be tightly regulated to avoid detrimental effects, as both
increased and decreased expression of SNCA has been
linked to an increase in PD risk.
It is obvious that there is a relation between cell pro-
liferation, death and survival and that SNCA orchestrates,
in an unknown way, cell fate decisions. In particular, it
appears essential that SNCA expression and function be
tightly regulated in the neuronal cells, as any changes in the
expression levels (increased or decreased) or in the SNCA
genetic sequence lead to defects in both embryonic and
adult neurogenesis. In particular, the documented decrease
in DA neurogenesis may suggest that individuals with
SNCA mutations are born with less DA neurons and would
therefore be more susceptible to PD. Still, PD symptoms
would occur later in life due to the normal decline in
neurogenesis with age. Mutant forms of SNCA would
exasperate the neurogenesis decline; the accumulated
decline in neurogenesis (from age and SNCA mutations)
may bring it under a certain threshold, leading to the
occurrence of non-motor symptoms.
LRRK2 (PARK8)
Mutations in the LRRK2 gene (12q12), located at the
PARK8 locus, are the most common cause of autosomal
dominant PD, accounting for 1–40 % of all the cases
depending on the populations, and up to 5 % of apparently
sporadic cases [185, 186]. PD-related LRRK2 gene muta-
tions include R1441C, R1441G, Y1699C, G2019S and
I2020T [187–191]. The G2019S and R1141G mutations,
which increase kinase activity and decrease GTPase
activity, respectively, are the two most common PD-asso-
ciated mutations in LRRK2 [192–194].
The LRRK2 gene encodes for the leucine-rich repeat
kinase (LRRK2) protein, a large and complex protein
comprised of multiple domains, including a central cata-
lytic tridomain with GTPase and kinase activities
surrounded by several potential protein–protein interaction
domains [187, 188]. Despite the knowledge regarding
LRRK2 protein structure and its mRNA and protein
expression, the precise physiological function of LRRK2
remains unclear.
LRRK2 shows widespread expression throughout the
brain at both the mRNA and protein level [76]. In the
mouse brain, LRRK2 mRNA is first detected at E16 and
increases as development progresses through postnatal
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periods [195]. It is a ubiquitous protein expressed in vari-
ous brain regions and various cell types, including neurons
and glial cells. LRRK2 has been described to display robust
expression in areas with ‘‘high proliferative and migratory
activity as well as sites of differentiation and cell death’’
[76]. In particular, it is expressed in the main neurogenic
niches of the mammalian brain: the ventricular zone, SVZ
and hippocampus [195]. Moreover, LRRK2 co-localizes
with the migrating NB marker PSA-NCAM [195]. Alto-
gether, the expression pattern of LRRK2 suggests a role for
this protein in CNS development and neurogenesis.
Reduced expression of LRRK2
Although LRRK2 KO mice do not appear to exhibit any
alterations in neuronal function or survival [196], the dif-
ferent NSC gene expression profiles in the presence or
absence of LRRK2 expression demonstrate that the absence
of LRRK2 protein affects a number of different cellular
processes, including genes implicated in cell cycle regu-
lation, ribosome biosynthesis, proteasome function and
mitochondrial oxidation or reduction processes [197].
LRRK2 loss of function does not affect NSC self-
renewal in in vitro cultures, nor does it affect cell prolif-
eration in the adult DG of LRRK2 KO mice [94, 197].
LRRK2 deficiency has, however, been linked to an increase
in neuronal commitment in vitro and an increase in
immature NBs due to delayed neuronal maturation in the
adult DG [94, 197, 198]. In fact, neuronal differentiation
appears to be closely linked to LRRK2 protein expression
levels, as even a 50 % decrease of this protein’s expression
levels in LRRK2 heterozygote ESCs appears to accelerate
retinoic acid-induced neuronal differentiation [198]. This
was visible through a differential gene expression analysis
that revealed accelerated silencing of ESC pluripotency
markers and downstream targets as well as increased
expression of voltage-gated ion channels and neurotrans-
mitter receptors or transporters in LRRK2 heterozygous
cells 7 days after retinoic acid-induced neuronal differen-
tiation. This effect may be mediated through the alleviation
of let-7 miRNA (a key pro-differentiation miRNA, dis-
cussed further below) suppression via Lin28. Indeed, the
reduction in Lin28 expression was also exaggerated in
LRRK2 heterozygous cells compared to WT cells during
differentiation.
The sum of these studies demonstrates that LRRK2 is
implicated in early neuronal differentiation and appears to
negatively regulate this process. Of note, another study
utilizing siRNA-mediated KD of LRRK2 in NPCs did not
observe a difference in the number of total neurons after
neuronal differentiation but instead observed a difference
in the number of TH? neurons, suggesting a reduced
capacity of these cells to differentiate into DA neurons
[199]. Varying the expression levels of LRRK2 may,
therefore, differentially affect the genesis of specific neu-
ronal populations.
Overexpression of mutated LRRK2
Overexpression of PD-related mutant G2019S LRRK2
protein produces defects in adult neurogenesis, at the level
of cell proliferation and generation of newborn neurons.
Indeed, transgenic mice overexpressing the PD-associated
human LRRK2 G2019S protein display a significant
decrease in the number of proliferating (BrdU positive)
cells in the adult DG, SVZ and RMS and decreased neu-
rogenesis (BrdU and NeuN positive) and DA neurogenesis
(BrdU, NeuN and TH positive) as well as decreased sur-
vival of newly generated neurons in the OB [86]. The
LRRK2 G2019S mutation may contribute to the hippo-
campal and SVZ-related age-dependent non-motor
symptoms via dysfunctions in the NSC pool and in their
neural derivatives at early stages of maturation. Indeed,
LRRK2 G2019S iPSC-derived NSCs in culture, especially
at late passages, display increased susceptibility to prote-
asomal stress and a passage-dependent decrease in clonal
expansion and neuronal differentiation capacities [200].
LRRK2 regulates microRNAs
microRNAs, also known as miRNAs, are short (20–25
nucleotides) endogenous RNAs that regulate gene expres-
sion at the mRNA level. Briefly, pre-miRNAs are recruited
to the miRNA-induced silencing complex, containing at
least the Dicer protein, the double-stranded RNA-binding
domain protein transactivation-responsive RNA-binding
protein and a member of the Argonaut family [201]. The
pre-miRNA is then processed by Dicer [202] and the
mature miRNA guides the miRNA-induced silencing
complex to the target mRNA sequence, via complementary
base pairing, to downregulate its expression through
translational repression, mRNA degradation or mRNA
cleavage [203]. Several miRNAs are specifically enriched
in the brain and the necessity of miRNA regulation for
normal brain development has been the subject of several
recent reviews [204–206]. What is more, miRNAs are
regulators of NSC proliferation and differentiation and
several studies have linked deregulated miRNA expression
or function in the brain or in NSCs with PD pathogenesis
(reviewed in [207, 208]).
Although miRNAs were initially described to function
upstream of protein expression by targeting the mRNA of
disease-associated genes to direct their posttranscriptional
repression, more recent studies have demonstrated that
some disease-associated proteins are also involved in the
regulation of miRNAs pathways. For example, in
782 J. N. Le Grand et al.
123
Drosophila, pathogenic LRRK2 antagonizes let-7 and miR-
184*; transgenic flies carrying the equivalent of the human
G2019S mutation displayed increased inhibition of let-7
and miR184* activity [209]. Furthermore, the effect of
pathogenic LRRK2, at least on let-7 inhibition, was
dependent on its kinase activity, evident by the fact that the
introduction of kinase-inactivating mutations abolished the
observed effect. let-7 and miR184* are implicated in the
repression of E2F and DP, respectively. These transcription
factors are involved in cell cycle control and survival. As
such, their repression results in a reduction in locomotor
activity and an enhanced neuronal degeneration phenotype,
suggesting another mechanism of miRNA pathway regu-
lation in LRRK2-associated PD.
Additionally, Bahnassawy and collaborators investi-
gated miRNA regulation by the R1441G mutation, the
second most common PD-associated LRRK2 mutation.
They showed that expression of R1441G LRRK2 in murine
NSCs leads to a downregulation of let-7a and miR-9,
although LRRK2 deficiency did not affect microRNA
expression levels [197]. Altogether, these studies point to
an important role for the LRRK2 gene in the pathogenesis
of PD, mediated through miRNA regulatory pathways and
point to future possible targets in the search for new ther-
apeutic strategies for PD.
LRRK2 is involved in Wnt signaling
In addition to its role in the regulation of NSC differenti-
ation, LRRK2 has been suggested to play a role in
neurogenesis. Correspondingly, Berwick and Harvey have
proposed that LRRK2 functions as a scaffolding protein
that plays a role in numerous signaling pathways, thus
linking LRRK2 to neurogenesis and to the function of post-
mitotic and mature neurons [210]. The canonical Wnt/b-
catenin pathway is part of the signaling mechanisms
involved in the regulation of embryonic and adult neuro-
genesis, and in particular in the development of DA
neurons. It plays a role in the regulation of axonal guid-
ance, dendritic morphogenesis and synapse formation. Wnt
cascades have been implicated in PD and deregulated Wnt
signaling represents a feasible initiation event in neurode-
generation [211].
LRRK2 has been associated to Wnt signaling via its
interaction with key components of the Wnt signaling
pathway, such as DVL, the b-catenin destruction com-
plex and LRP6 [95, 96]. Moreover, it has been
demonstrated that pathogenic mutations of LRRK2
modulate its interaction with different Wnt pathway
molecules, including DVL and GSK3, a component of
the b-catenin destruction complex [83, 95]. Importantly,
KD of LRRK2 results in enhanced canonical Wnt sig-
naling [96]. This data suggest that LRRK2 plays a
central role in Wnt signaling, an essential pathway in
NSC biology and neurogenesis.
Despite the growing body of knowledge concerning the
LRRK2 gene and its PD-related mutations, the molecular
and cellular implications of LRRK2 mutations during the
onset and progression of PD still remain unknown. Given
LRRK2’s implication in neurogenesis and the parallels
between neurogenic niches and brain regions implicated in
non-motor PD symptoms, it is likely that LRRK2 mutations
are responsible for some of the non-motor symptoms
related to PD.
VPS35 (PARK17)
The VPS35 gene (16q12) is located at the PARK17 locus
and codes for the vacuolar protein sorting 35 (VPS35).
Recently, the p.D620N mutation in the VPS35 gene was
identified as a novel cause of autosomal dominant late-
onset PD by two research groups [212, 213] and five
subsequent studies have identified this mutation in PD
patients [214–217]. Moreover, PD-associated defects in
RAB7L1 or LRRK2 lead to a deficiency of the VPS35
component of the retromer complex [218].
VPS35, along with VPS26 and VPS29, makes up the
cargo recognition and binding subcomplex of the retromer,
an important complex for the trafficking and recycling of
lipids and proteins [219–221]. The D620N PD-related
mutation in VPS35 displays a dominant negative missort-
ing phenotype of retrograde transport of proteins dependent
on the WASH complex [218, 222]. WT VPS35 regulates
mitochondrial-anchored protein ligase transport from the
mitochondria to the peroxisomes [223], suggesting that
VPS35 mutations may produce mitochondrial defects in
patients. VPS35 is also responsible for divalent metal
transporter 1 transport [224]. Mutated VPS35 may, there-
fore, lead to divalent metal transporter 1 missorting and
iron accumulation, similar to the iron accumulation
described in PD patients and in the 6-OHDA mouse model
of PD [225]. Finally, VPS35 is also hypothesized to
influence the Wnt signaling pathway via deficient sorting
of the Wntless protein, which leads to Wntless degradation
[226–228] and Wnt/b-catenin signaling is impaired in
6-OHDA-lesioned rats [229] and MPTP-induced mouse
and monkey models [230].
As previously mentioned, Wnt signaling plays a role in
embryonic and adult neurogenesis and has been linked to
PD. As such, the PD-related VPS35 mutation (D620N) may
also have an effect on neurogenesis in the PD brain. Little
is known about the role of VPS35 in neurogenesis partly
because homozygous KO mice die early during embryonic
development, before E10 and before the onset of neuro-
genesis [231]. In one study focusing on Alzheimer’s
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disease by Wang et al. [97], VPS35 was shown to promote
apical dendritic growth and maturation and axonal protein
transport in developing mouse hippocampal neurons. The
authors demonstrated that embryonic hippocampal CA1
neurons with reduced VPS35 expression (via electropora-
tion with microRNAs) display shortened apical dendrites,
less dendritic spines and swollen commissural axons. The
authors suggest that these observations reflect a defective
protein transport in developing mouse neurons via
impaired retrograde trafficking of beta1-secretase and
altered beta1-secretase distribution. Similarly, KD of
VPS35 or overexpression of D620N VPS35 in rat primary
cortical cultures leads to a reduction in neurite length
[218]. It will be interesting in the future to see if this
protein also plays a role in the development or maintenance
of other neuronal types in the adult brain as well as during
embryonic neurogenesis. One could hypothesize that the
dominant negative VPS35 mutant may drastically decrease
the survival of newly generated neurons by inhibiting
proper retrograde transport of important trophic factors and
by inhibiting normal neurite outgrowth.
Of note, in a non-neuronal system, the mouse intestinal
epithelium, although depletion of VPS35 does reduce
Wntless protein levels, it did not affect stem cell prolifer-
ation in intestinal epithelium-derived cell cultures but did
slightly reduced the growth rate of in vitro organoids
derived from these cultures [232]. Given its role in Wnt
signaling, it is not surprising that the loss of normal VPS35
function results in a decreased proliferative phenotype. It
will be interesting to see if this phenotype is reproduced or
even exaggerated in other systems such as during devel-
opment of the CNS, in which Wnt signaling is required for
long-distance gradient formation to guide NB migration
and to establish neuronal polarity. Recalling that Wnt
signaling has been implicated in the development of mid-
brain DA neurons, we can then hypothesize that disruption
of Wnt signaling via the D620N VPS35 mutation has the
potential to decrease the number of DA neurons formed
during embryonic development, resulting in fewer DA
neurons at birth, thus increasing an individual’s suscepti-
bility to PD. Moreover, defects in adult neurogenesis
caused by a disruption in Wnt signaling are likely to con-
tribute to the non-motor symptoms observed in PD.
Finally, the D620N VPS35 mutation has also been
shown to impair the autophagic process via missorting of
the autophagic protein, Atg9, thought to contribute to
autophagosome formation [222]. Several studies using
mice deficient for autophagy-related genes have outlined
the importance of the autophagic machinery in embryonic
development of the CNS [233–236]. In particular,
autophagy is necessary for proper neuronal differentiation
[237, 238]. It will be interesting in the future to evaluate if
impaired autophagosome formation caused by the PD-
related VPS35 mutation also leads to impaired neurogen-
esis via defects in neuronal differentiation.
PINK1 (PARK6)
More than 50 mutations in the PINK1 gene (1p36), located
at the PARK6 locus, have been identified in PD-affected
patients [239–243] and these mutations are believed to
account for up to 1–8 % of sporadic cases with early onset
[244].
PTEN-induced putative kinase 1 (PINK1) is a serine/
threonine kinase protein localized to the mitochondrial
matrix and the intermembrane space [245, 246]. Under
normal conditions, it is rapidly degraded but when the
mitochondrial membrane is compromised, PINK1 is sta-
bilized at the outer mitochondrial membrane where it
recruits the E3-like ligase protein, Parkin, which in turn
ubiquitinates other matrix surface proteins and targets the
damaged mitochondria for autophagic degradation [247,
248].
PINK1 transcripts are ubiquitously expressed in the
murine brain, including brain structures in which neuro-
genesis still occurs in the adult such as the hippocampus
[249]. PINK1 expression has also been confirmed in human
NSCs using RT-PCR. Interestingly, PINK1 expression
increases 100-fold following differentiation to DA neurons
[250]. In the latter study, the authors created a stable
PINK1 KD human NSC line using RNAi methods to study
this proteins’ function in NSC-derived mature DA neurons.
Although PINK1 expression was reduced by[90 % in the
selected clone, these NSCs displayed a similar DA neuron
differentiation efficiency as the WT controls, suggesting
that PINK1 is not necessary for DA neuronal
differentiation.
In another study, the role of PINK1 was examined in
human iPSCs derived from a patient with a PD-associated
PINK1 mutation (Q456X) that results in a premature stop
codon and results in a 80–90 % reduction in PINK1 mRNA
levels compared to human iPSCs derived from a healthy
family member [251, 252]. iPSCs derived from the fibro-
blasts of the PD patient were comparable to WT iPSCs;
they displayed a high expression of the pluripotency
markers OCT4a, Tra-1-60, NANOG and SSEA-4 at both
protein and transcript levels; the iPSC-derived embryonic
bodies were able to differentiate into the three embryonic
germ layers; and the iPSCs displayed a normal karyotype.
Once again, the decreased expression of PINK1 in the
mutant iPSCs did not impede DA neuronal differentiation,
as was demonstrated by a slightly higher number of TH-
positive neurons in the PINK1 mutant-derived cells.
Similar observations were made in a third study done by
Cooper and colleagues in 2012 in which human iPSCs
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were again derived from patients with the Q456X PINK1
mutation [253]. Supplementary results to validate the cel-
lular model confirmed that the PINK1 mutant iPSCs are
able to differentiate into all the neuronal lineages including
DA neurons and display normal karyotyping. As only one
PINK1 mutation has been studied with respect to neuro-
genesis defects, future studies will be needed to determine
if other PINK1 mutations affect DA neurogenesis or DA
neuronal differentiation.
All the above studies focused on DA neuron differen-
tiation in cells with reduced, but not absence of, PINK1
expression. By contrast, in drosophila neuroblasts (dNB)
and mammalian NSCs, PINK1 deficiency is inversely
related to dNB maintenance and cell proliferation [254].
The number of type II dNBs, which contain transit-
amplifying intermediate progenitors and are similar to
mammalian NSCs, was significantly reduced in PINK1-
null Drosophila mutants. Moreover, RNAi KD of dPINK1
blocks activation of mTORC2 and formation of ectopic
NBs. In human NSC cultures, shRNA KD of PINK1 sig-
nificantly inhibited cell proliferation. This effect appeared
to be regulated by a non-canonical Notch signaling
involving PINK1, mTORC2 and phosphorylated AKT, in
which Notch directly interacts with PINK1 at the mito-
chondria. Indeed, Notch signaling is implicated in neuronal
precursor cell proliferation and loss of function mutations
of Notch leads to early neuronal differentiation and a
decrease in the number of neuronal precursor cells [255,
256].
As previously mentioned, the PINK1 protein is impor-
tant for mitochondrial quality control via autophagic
degradation of damaged mitochondria. Mitochondria may
play a role in stem cell proliferation by reducing mito-
chondrial oxygen levels, a phenomenon that enhances both
ESC and NSC proliferation and differentiation potential
[257–259], and by reducing mitochondrial Ca2? levels, that
are increased, along with mitochondrial fusion, during
neuronal differentiation [260]. Loss of normal mitochon-
drial function may also contribute to the observed decrease
in proliferation in the PINK1 KD experiments.
Although little research has been done to date on the
implication of the PINK1 protein in neurogenesis, the little
data thus far would suggest that the PINK1 loss of function
mutations results in a decrease of NSC proliferation.
Moreover, conditional PINK1 KO mice display impaired
olfaction [261], which is a non-motor symptom of PD and a
phenotype that can be attributed to impaired neurogenesis.
Parkin (PARK2)
Parkin deletion mutations are a common cause of early-
onset PD and over 100 mutations have been identified to
date [262–266]. The Parkin gene, located at the PARK2
locus (6q25.2-q27), is mutated in up to 50 % of all
familial PD cases and in 10–15 % of sporadic early-onset
PD [267].
The Parkin gene, located at the PARK2 locus, codes for
the protein Parkin, an E3 ubiquitin ligase enzyme that is
involved in proteasome-mediated and autophagy-mediated
degradation of several substrates, particularly mitochondria
[268]. During membrane depolarization or in the presence
of reactive oxygen species, Parkin is recruited to the
mitochondrial membrane by PINK1 and ubiquitinates
mitochondrial proteins, targeting them for autophagic
degradation [269]. PD-related mutations in Parkin result in
the loss of its ubiquitin ligase activity [268]. Parkin KO
mice display decreased levels of proteins involved in
mitochondrial function or oxidative stress [270] and Parkin
KO Drosophila display a mitochondrial pathology [271].
Given its role in mitochondrial quality control, Parkin
mutations may act similarly to PINK1 loss of function and
affect neuronal differentiation, via abnormal mitochondrial
activity. Moreover, the Parkin protein ubiquitinates the
neuronal cell fate determinant TRIM32, which in turn
regulates NSC differentiation [272–275]. However, the
experimental evidence for a role for Parkin in neuronal
differentiation, outlined below, is contradictory.
Parkin KO ESCs display the same efficiency of
in vitro neuronal differentiation as the WT ESCs, in par-
ticular the expression of the DA neuronal marker, TH, was
the same in both WT and KO ESC-derived neurons [276].
RT-PCR analysis of these neurons revealed similar
amounts of all transcripts examined, including the tran-
scription factors Nurr1 and Pitx3, the enzymatic proteins
TH and AADC, and the DA receptor, D2R.
In other studies, iPSCs derived from Parkin mutation
related PD patients with homozygous or heterozygous
deletions for a variety of different exons were created and
compared to control iPSCs. Again, the mutant iPSCs dis-
played the same human pluripotent stem cell markers as
their WT counterparts and were capable of generating
embryonic bodies as well as neurospheres and differenti-
ating into DA neurons [277, 278].
On the other hand, the drosophila Parkin protein has
been shown to interact with clueless [279], which regulates
atypical protein kinase C (aPKC) activity, a protein that is
involved in NB asymmetric division, giving rise to both
NBs and newly generated neurons [280]. Interestingly,
both clueless and park (drosophila Parkin gene) mutants
display similar Parkinsonian phenotypes and mitochondrial
defects [279] as well as a similar NB phenotype, namely
mislocalized cell fate determinants [281]. Furthermore,
aPKC has been previously shown to regulate the neuronal
cell fate determinant TRIM32 [272]. Together, these
results suggest that, in Drosophila, Parkin is involved in
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the same neurogenic pathway as clueless, although further
studies will be necessary to confirm this hypothesis.
Finally, in vitro experiments have shown that, in SH-
SY5Y cells, PINK1 phosphorylates Parkin and activates its
E3 ubiquitin ligase activity, which in turn adds K63-linked
polyubiquitination chains to nuclear factor-kappaB (NF-
jB), activating NF-jB signaling [282], a known regulator
of embryonic and adult neurogenesis and neuronal differ-
entiation. PD-related mutations in PINK1 (G309D, L347P)
disrupt PINK1 kinase function [283–285] and are unable to
phosphorylate Parkin and therefore unable to activate NF-
jB signaling, suggesting that neurogenesis may also be
disrupted in these PD genetic models. These findings and
the subsequent effect on neurogenesis will need to be
confirmed in in vivo models of PINK1 and Parkin
mutations.
Although very little evidence exists linking PD-related
Parkin mutations to neurogenesis and non-motor symp-
toms of PD, clearly this protein is implicated in several
neurogenesis-related pathways, including mitochondrial
quality control in neuronal differentiation, TRIM32 ubiq-
uitination in cell fate determination, regulation of aPKC in
stem cell renewal regulation and NF-jB signaling in adult
neurogenesis and neuronal differentiation.
DJ-1 (PARK7)
Over 10 different mutations in the DJ-1 gene (1p36.23),
located at the PARK7 locus, are responsible for 1–2 % of
early-onset cases of autosomal recessive PD [286–288].
Originally identified as an oncogene, DJ-1 is thought to
act as a molecular chaperone protein [289–291], an oxi-
dative sensor and antioxidant [292–294] and in the
regulation of gene transcription [295]. DJ-1 mutations can
reduce DJ-1 protein synthesis or increase DJ-1 protein
degradation [296]. In the cell, DJ-1 is expressed in the
nucleus and the cytosol [297, 298]. Nuclear DJ-1 forms a
complex with RNA-binding proteins and DNA-binding
proteins that regulate gene transcription [295], while
cytosolic DJ-1 can be found in several pools, including in
the intermembrane space and matrix of the mitochondria.
DJ-1 is expressed in the cytosol of Nestin-positive cor-
tical NSCs cultured from E14 rats, as well as in vivo, in the
same cortical region and in rat NSC-derived neurospheres
during proliferation [298]. DJ-1 may protect NSCs during
proliferation through its antioxidant activity. Indeed, DJ-1
plays a role in the protection against oxidative stress and
oxygen–glucose deprivation in human NPCs in culture
[299] and DJ-1 deficiency in murine ESCs causes increased
sensitivity to oxidative stress (increased apoptotic cell
death after H2O2 treatment) and to proteasomal inhibition
(increased sensitivity to the proteasomal inhibitor
lactacystin) [300]. These results underline the importance
of this protein in the protection of these highly proliferative
cells against accumulation of deleterious ROS or accu-
mulating proteins.
DJ-1 protein expression has also been described in both
midbrain- and hippocampal-derived NSC neurospheres, in
cells within the neurospheres as well as in cells migrating
from the spheres [301]. During differentiation of cultured
NSCs, DJ-1 expression increases gradually although the
percentage of neuron-specific enolase NSE/DJ-1 colocal-
isation in neurons was less than 5 %, while the percentage
of glial fibrillary acidic protein/DJ-1 colocalisation in
astrocytes increased gradually to 85 % at day 7 of differ-
entiation [297]. This is in accordance with the fact that, in
the brain, DJ-1 is expressed mainly in astrocytes [302]. By
contrast, another study has demonstrated a high level of
DJ-1 expression in ESCs and a downregulation of DJ-1
expression to null amounts in these cells as they differen-
tiate to cardiomyocytes [303], suggesting that any role for
this protein in differentiation is likely specific to neural
lineages. DJ-1 may play a role in NSC differentiation by
acting as a scavenger of ROS, since controlled generation
of ROS can stimulate differentiation via regulation of
redox-sensitive transcription factors important for neuro-
genesis such as NF-jB and AP-1 [304, 305].
Conclusions
The studies described in this review demonstrate a link
between defects in NSC characteristics, neurogenesis and
PD. It suggests that some of the non-motor symptoms
observed early in PD are likely due to defects in embryonic
neuronal development as well as defects in adult neuro-
genesis. Furthermore, they underscore that PD has a strong
developmental component. A better understanding of the
interplay between deficits in embryonic and adult neuro-
genesis and PD onset and progression will be key to the
development of better treatments for this debilitating dis-
ease. In particular, the adult SVZ contains a source of
endogenous NSCs that are capable of differentiating into
DA and non-DA neurons. As such, treatments that can
restore impaired neurogenesis in PD patients could provide
a source of endogenous repair. It may be time to change the
way we look at this neurodegenerative disease, to start
considering the possibility that PD starts much earlier than
DA neuron degeneration and to consider that develop-
mental and adult neurogenesis are key players in onset and
progression of this disease.
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